<p>低買高賣。這一直是投資者長期以來的良好策略。然而，考慮到 <strong>標準普爾 500 指數</strong> 接近歷史最高點，按照這種方法找到值得購買的優質股票可能看起來很困難。</p>
<p>好消息是，這樣做比你想象的要容易。以下是三隻接近 52 周低點的優秀股票。</p>
<h2>1. D.R. Horton</h2>
<p><strong>D.R. Horton</strong>(DHI 0.95%)，美國最大的住宅建築商，在過去 12 個月裏讓投資者經歷了一場過山車般的旅程。不過，最近的旅程並不愉快，股票價格比 9 月份的峯值下跌了超過 30%，僅略高於其 52 周低點。</p>
<p>D.R. Horton 面臨的主要問題可以用兩個詞來概括：抵押貸款利率。儘管美聯儲去年底降低了基準利率，但抵押貸款利率依然頑固地高企。當抵押貸款利率高時，越來越少的美國人能夠負擔得起購買新房。</p>
<p>抵押貸款利率會很快下降嗎？我不知道。不過我知道的是，美國房地產市場的長期前景依然強勁——這對 D.R. Horton 在未來十年是個好兆頭。</p>
<p>我還知道 D.R. Horton 的估值很有吸引力。其股票的預期前瞻性市盈率僅為 9.9 倍。即使是關於抵押貸款利率的積極消息也可能為這隻被打壓的股票提供一個良好的催化劑。</p>
<h2>2. Pfizer</h2>
<p><strong>Pfizer</strong>(PFE -0.43%) 的股票自 2021 年底以來一直處於普遍下滑的軌道。這一時機與全球接近走出 COVID-19 疫情的時刻不謀而合。隨着 Pfizer 的 COVID-19 疫苗和抗病毒藥物銷售下滑，其股價也隨之下跌。這隻大型製藥公司的股票現在接近過去 52 周的最低水平。</p>
<p>當然，Pfizer 仍面臨一些挑戰。特別是，未來幾年內其幾款產品將失去專利獨佔權，其中包括重磅藥物 Eliquis、Ibrance 和 Xtandi。COVID-19 疫苗銷售回到接近峯值水平的機會也微乎其微。</p>
<p>然而，Pfizer 相信它將在本十年的下半年實現穩健增長。怎麼做到的？該公司的產品線中有一些新興明星，如偏頭痛治療藥物 Nurtec ODT 和癌症藥物 Padcev、Adcetris 和 Tukysa。Pfizer 的研發管線中還有 115 個候選藥物，其中五個正在等待監管批准，32 個處於後期臨牀測試階段。</p>
<p>與此同時，Pfizer 的股票便宜，前瞻性市盈率僅為 8.7 倍。這家制藥公司還支付股息，目前股價的前瞻性收益率超過 6.7%。</p>
<h2>3. 聯合包裹</h2>
<p><strong>聯合包裹</strong>(UPS 0.50%) 的股票在過去 12 個月中暴跌了約 20%。儘管最近幾天小幅反彈，但該股票仍然接近其 52 周低點。</p>
<p>許多投資者對 UPS 決定到明年下半年將與 <strong>亞馬遜</strong> 的業務量削減超過 50% 並不滿意。有些人認為這一舉動不明智，因為亞馬遜是這家包裹遞送公司的最大客户。</p>
<p>UPS 的管理團隊瘋了嗎？我不這麼認為。為亞馬遜運輸貨物對 UPS 來説並不是一項特別有利可圖的業務。逐漸減少與這家電子商務巨頭的運輸量，同時縮減資產和資源，應該會提高 UPS 的盈利能力，儘管收入下降。UPS 還將尋求通過擴大與其他（更有利可圖的）客户的業務來抵消部分收入損失。</p>
<p>收入投資者仍然應該喜歡 UPS 的前瞻性股息收益率為 5.6%。該公司已經連續 16 年增加股息。儘管近年來的增幅較小，但 UPS 的股息似乎是安全的。</p>

霍頓房屋

聯合包裹

<p>三隻接近 52 周低點的股票被強調為潛在投資：1. D.R. Horton (DHI) 是美國最大的住宅建築商，面臨高抵押貸款利率的挑戰，但長期前景良好，估值具有吸引力。2. 輝瑞 (PFE) 由於 COVID-19 產品銷售下降而出現下滑，但擁有有前景的產品線和高股息收益率。3. 聯合包裹 (UPS) 減少了與亞馬遜的業務，但旨在通過專注於更有利可圖的客户來提高盈利能力，同時保持穩健的股息收益率</p>

<p>Buy low, sell high. That has been a good strategy for investors for a long time. However, finding great stocks to buy under this approach might seem difficult right now, considering that the <strong>S&amp;P 500</strong> is close to its all-time high.</p>
<div class="lb-trans"><p>低買高賣。這一直是投資者長期以來的良好策略。然而，考慮到 <strong>標準普爾 500 指數</strong> 接近歷史最高點，按照這種方法找到值得購買的優質股票可能看起來很困難。</p>
</div><p>The good news is that doing so is easier than you might think. Here are three magnificent stocks to buy that are near their 52-week lows.</p>
<div class="lb-trans"><p>好消息是，這樣做比你想象的要容易。以下是三隻接近 52 周低點的優秀股票。</p>
</div><h2>1. D.R. Horton</h2>
<div class="lb-trans"><h2>1. D.R. Horton</h2>
</div><p><strong>D.R. Horton</strong>(DHI 0.95%), the largest U.S. homebuilder by volume, has taken investors on a roller-coaster ride over the last 12 months. The ride hasn't been much fun lately, though, with the stock down more than 30% from the peak it set in September and barely above its 52-week low.</p>
<div class="lb-trans"><p><strong>D.R. Horton</strong>(DHI 0.95%)，美國最大的住宅建築商，在過去 12 個月裏讓投資者經歷了一場過山車般的旅程。不過，最近的旅程並不愉快，股票價格比 9 月份的峯值下跌了超過 30%，僅略高於其 52 周低點。</p>
</div><p>The main problem for D.R. Horton can be summed up in two words: mortgage rates. They remain stubbornly high despite the Federal Reserve's cuts to its benchmark interest rate late last year. When mortgage rates are high, fewer Americans can afford to buy new homes.</p>
<div class="lb-trans"><p>D.R. Horton 面臨的主要問題可以用兩個詞來概括：抵押貸款利率。儘管美聯儲去年底降低了基準利率，但抵押貸款利率依然頑固地高企。當抵押貸款利率高時，越來越少的美國人能夠負擔得起購買新房。</p>
</div><p>Will mortgage rates decline soon? I don't know. What I do know, though, is that the long-term prospects for the U.S. housing market remain strong -- and that bodes well for D.R. Horton over the next decade.</p>
<div class="lb-trans"><p>抵押貸款利率會很快下降嗎？我不知道。不過我知道的是，美國房地產市場的長期前景依然強勁——這對 D.R. Horton 在未來十年是個好兆頭。</p>
</div><p>I also know that D.R. Horton's valuation is attractive. Its shares trade at only 9.9 times expected forward earnings. Even a hint of positive news on mortgage rates could provide a nice catalyst for this beaten-down stock.</p>
<div class="lb-trans"><p>我還知道 D.R. Horton 的估值很有吸引力。其股票的預期前瞻性市盈率僅為 9.9 倍。即使是關於抵押貸款利率的積極消息也可能為這隻被打壓的股票提供一個良好的催化劑。</p>
</div><h2>2. Pfizer</h2>
<div class="lb-trans"><h2>2. Pfizer</h2>
</div><p><strong>Pfizer</strong>(PFE -0.43%) stock has been on a generally downward trajectory since late 2021. That timing not-so-coincidentally roughly matches when the world was close to turning the corner on the COVID-19 pandemic. As sales for Pfizer's COVID-19 vaccines and antivirals sank, so did its share price. The big pharma stock is now near its lowest level of the last 52 weeks.</p>
<div class="lb-trans"><p><strong>Pfizer</strong>(PFE -0.43%) 的股票自 2021 年底以來一直處於普遍下滑的軌道。這一時機與全球接近走出 COVID-19 疫情的時刻不謀而合。隨着 Pfizer 的 COVID-19 疫苗和抗病毒藥物銷售下滑，其股價也隨之下跌。這隻大型製藥公司的股票現在接近過去 52 周的最低水平。</p>
</div><p>To be sure, Pfizer still faces some challenges. In particular, several of its products will lose patent exclusivity over the next few years, among them blockbuster drugs Eliquis, Ibrance, and Xtandi. The chances of COVID-19 vaccine sales returning to anywhere close to their peak levels are also slim to none.</p>
<div class="lb-trans"><p>當然，Pfizer 仍面臨一些挑戰。特別是，未來幾年內其幾款產品將失去專利獨佔權，其中包括重磅藥物 Eliquis、Ibrance 和 Xtandi。COVID-19 疫苗銷售回到接近峯值水平的機會也微乎其微。</p>
</div><p>However, Pfizer believes it will be able to deliver solid growth in the second half of this decade. How? The company's product lineup features rising stars such as migraine therapy Nurtec ODT and cancer drugs Padcev, Adcetris, and Tukysa. Pfizer's pipeline also includes 115 candidates, five of which are awaiting regulatory approvals and 32 that are in late-stage clinical testing.</p>
<div class="lb-trans"><p>然而，Pfizer 相信它將在本十年的下半年實現穩健增長。怎麼做到的？該公司的產品線中有一些新興明星，如偏頭痛治療藥物 Nurtec ODT 和癌症藥物 Padcev、Adcetris 和 Tukysa。Pfizer 的研發管線中還有 115 個候選藥物，其中五個正在等待監管批准，32 個處於後期臨牀測試階段。</p>
</div><p>Meanwhile, Pfizer stock is cheap, with a forward earnings multiple of only 8.7. The drugmaker also pays a dividend with a juicy forward yield north of 6.7% at the current share price.</p>
<div class="lb-trans"><p>與此同時，Pfizer 的股票便宜，前瞻性市盈率僅為 8.7 倍。這家制藥公司還支付股息，目前股價的前瞻性收益率超過 6.7%。</p>
</div><h2>3. United Parcel Service</h2>
<div class="lb-trans"><h2>3. 聯合包裹</h2>
</div><p>Shares of <strong>United Parcel Service</strong>(UPS 0.50%) have plunged by roughly 20% over the last 12 months. Despite a small bounce in recent days, the stock remains within striking distance of its 52-week low.</p>
<div class="lb-trans"><p><strong>聯合包裹</strong>(UPS 0.50%) 的股票在過去 12 個月中暴跌了約 20%。儘管最近幾天小幅反彈，但該股票仍然接近其 52 周低點。</p>
</div><p>Many investors weren't happy with UPS' decision to slash the volume of business it does with <strong>Amazon</strong> by more than 50% by the second half of next year. Some thought this move was ill-advised, considering that Amazon is the package delivery company's largest customer.</p>
<div class="lb-trans"><p>許多投資者對 UPS 決定到明年下半年將與 <strong>亞馬遜</strong> 的業務量削減超過 50% 並不滿意。有些人認為這一舉動不明智，因為亞馬遜是這家包裹遞送公司的最大客户。</p>
</div><p>Is UPS' management team crazy? I don't think so. Moving goods for Amazon isn't an especially profitable business for UPS. Gradually decreasing shipment volumes for the e-commerce giant while simultaneously scaling back assets and resources should boost UPS' profitability despite the lower revenue. UPS will also seek to offset some of that revenue loss by expanding its business with other (more profitable) customers.</p>
<div class="lb-trans"><p>UPS 的管理團隊瘋了嗎？我不這麼認為。為亞馬遜運輸貨物對 UPS 來説並不是一項特別有利可圖的業務。逐漸減少與這家電子商務巨頭的運輸量，同時縮減資產和資源，應該會提高 UPS 的盈利能力，儘管收入下降。UPS 還將尋求通過擴大與其他（更有利可圖的）客户的業務來抵消部分收入損失。</p>
</div><p>Income investors should still love UPS' forward dividend yield of 5.6%. The company has increased its payouts for 16 consecutive years. Although the hikes in recent years have been small, UPS' dividend appears to be safe.</p>
<div class="lb-trans"><p>收入投資者仍然應該喜歡 UPS 的前瞻性股息收益率為 5.6%。該公司已經連續 16 年增加股息。儘管近年來的增幅較小，但 UPS 的股息似乎是安全的。</p>
</div>

3 Magnificent Stocks to Buy That Are Near 52-Week Lows

- 當前市場接近歷史高點，尋找低價股票變得困難。  
- D.R. Horton、Pfizer 和 United Parcel Service 是接近 52 周低點的優質股票。  
- 這些公司在各自領域面臨挑戰，但長期前景仍然看好。

3 只接近 52 周低點的絕佳股票值得購買